| Detected | Trial | Change |
|---|---|---|
| 2026-07-31 | NCT05754658 African Cancer Genome: GMD |
Trial completed |
| 2026-07-31 | NCT05754658 African Cancer Genome: GMD |
Enrollment reduced: 1500 -> 854 participants |
| 2026-07-31 | NCT05754658 African Cancer Genome: GMD |
date change Primary completion pushed: 2025-12-31 -> 2026-07-10 |
| 2026-07-31 | NCT05754658 African Cancer Genome: GMD |
date change Completion pushed: 2025-12-31 -> 2026-07-10 |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT05454280 | Post-Discharge Risk-Based Management in Patients Undergoing High-Risk Elective Major… | Surgery | Recruiting |
| Phase 2 | |||
| NCT06914557 | Scrambler Therapy With Duloxetine-based Usual Care vs Duloxetine-based Usual Care for… | CIPN - Chemotherapy-Induced Peripheral Neuropathy | Recruiting |
| NCT07043972 | Gemcitabine and Carboplatin After Progression on Enfortumab Vedotin and Pembrolizumab in… | Urothelial Carcinoma | Recruiting |
| NCT07221942 | Pembrolizumab Maintenance After Enfortumab Vedotin (EV)/Pembro Induction in Front-Line… | Metastatic Urothelial Carcinoma | Recruiting |
| NCT05800574 | Lymphoscintigraphy Directed Elective Neck Radiation for p16+ Favorable Risk Oropharynx… | Oropharynx Cancer | Recruiting |
| NCT05800587 | Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | Lung Cancer | Recruiting |
| NCT05800600 | Iron Replacement to Reduce Anemia During Neoadjuvant Chemotherapy | Anemia | Recruiting |
| NCT05263050 | Trial of an Alternative Cabozantinib Dosing Schedule in Metastatic Renal Cell Carcinoma… | Metastatic Renal Cell Carcinoma | Recruiting |
| NCT03179943 | Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or… | Urothelial Carcinoma | Active, Not Recruiting |
| NCT06557330 | MRD Guided De-intensification of Bendamustine/Rituximab for Indolent Non-Hodgkin Lymphoma | Lymphoma | Not Yet Recruiting |
| NCT02755272 | A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic… | Carcinoma Breast Stage IV | Active, Not Recruiting |
| NCT04506554 | A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer | Muscle-Invasive Bladder Carcinoma | Active, Not Recruiting |
| NCT05360732 | Redefining FOLFIORINOX in Older Pancreatic Cancer Patients | Metastatic Pancreatic Cancer | Active, Not Recruiting |
| NCT05923190 | Enfortumab Vedotin Schedule De-escalation in Metastatic Urothelial Carcinoma | Urothelial Carcinoma | Active, Not Recruiting |
| NCT03114527 | Phase II Trial of Ribociclib and Everolimus in Advanced Dedifferentiated Liposarcoma… | Soft Tissue Sarcoma | Active, Not Recruiting |
| NCT03125928 | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients… | HER2-positive Breast Cancer | Active, Not Recruiting |
| NCT03527108 | Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT03548961 | Organ Preservation in Early Rectal Cancer Patients | Rectal Cancer | Active, Not Recruiting |
| NCT03786692 | Phase II Randomized Trial of Carboplatin+Pemetrexed+Bevacizumab+/- Atezolizumab in Stage… | Non-Small Cell Carcinoma of Lung, TNM Stage 4 | Active, Not Recruiting |
| NCT07663422 | Mycophenolate Mofetil w/ Prednisone for Immune Related Hepatitis From Checkpoint… | Immune-mediated Hepatitis | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT03172754 | Study of Nivolumab and Axitinib in Patients With Advanced Renal Cell Carcinoma | Renal Cell Carcinoma | Active, Not Recruiting |
| Phase 1 | |||
| NCT06218628 | Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2… | Primary Myelofibrosis | Recruiting |
| NCT04827810 | A Phase I Safety and Pharmacokinetic Study of Gamitrinib Administered Intravenously to… | Lymphoma | Recruiting |
| NCT05274048 | Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients | Gastric Cancer | Recruiting |
| NCT05880667 | Adaptive Radiation for Abdominopelvic Metastases | Neoplasm - Soft Tissue Pelvis Malignant Secondary | Recruiting |